Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

214results about "Nitro compound active ingredients" patented technology

Correlation of AKR1c3 enzyme expression level with KRAS mutation, and medical use

Correlation of the AKR1C3 enzyme expression level with KRAS mutation, and a medical use. For an AKR1C3 enzyme activated anti-cancer prodrug, KRAS gene mutation can directly serve as a test target before drug administration, that is, a patient with KRAS mutation is the patient having a high AKR1C3 enzyme expression level and AKR1C3 enzyme expression level or AKR1C3 RNA testing is not required. That is to say, a positive KRAS mutation testing result can be used as a screening index to screen the patient having a high AKR1C3 enzyme expression level.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Method for treating patient with BRCA-mutated cancer

A method for treating BRCA gene-mutated cancer. In the method, a drug containing hypoxia-activated prodrug compounds of formulas (1), (2) and (3) or AKR1C3 enzyme-activated prodrug compounds of formulas (4), (5), (6), (7), (8), (9), (10), (11) and (12) and salts, esters, solvates and isotopic isomers thereof, is used alone or in combination with other drugs to treat patients with BRCA gene-mutated cancer and tumors.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Method and composition for restoring homeostasis, treating, and preventing degenerative diseases, achieving Anti-aging effect

Disclosed are methods to restore homeostasis in a subject in need thereof; methods of treating or preventing a degenerative disease in a subject in need thereof; and methods of achieving anti-aging effect in a subject in need thereof. The disclosed methods establishes or rebuilds a homeostatic balance between electric and magnetic components of differential and integral characteristics of electromagnetic field in cells of said subject. The methods comprise administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising various essential chemical elements and additive chemical elements specific to each essential element.
Owner:VECTOR VITALE IP LLC

Cannabinoid receptor 2 modulators

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Compositions for topical treatment of microbial infections

The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.
Owner:HENNEPIN LIFE SCIENCES LLC

Method for treating cancer and tumor patients by combining AKR1c3 enzyme-activated compound and immune checkpoint inhibitor

A method for treating cancer or a tumor, in particular treating cancer by combining two drugs, relating to the field of cancer treatment. A method for treating cancer by combining a drug containing an AKR1C3 enzyme-activated compound and an immune checkpoint inhibitor / immune cell treatment drug. In particular, the immune checkpoint inhibitor is selected from an anti-PD -1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, etc., and the AKR1C3 enzyme-activated compound is selected from the compound of the following structure (I).
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Phenoxy (hetero) aryl ethers with anti-proliferative activity

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.
Owner:XENIOPRO GMBH

Type ii topoisomerase inhibitors and methods of making and using thereof

Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA are also described.
Owner:OHIO STATE INNOVATION FOUND

Methods for treating autism spectrum disorder

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).
Owner:THE GENERAL HOSPITAL CORP

Methods for treating and ameliorating cancer

In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S‐FD‐895 (or rebecsinib) and second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as dasatinib. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S‐FD‐895 and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre‐LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S‐FD‐895 and second drug.
Owner:RGT UNIV OF CALIFORNIA

Compositions and methods of treatment of disease using combination of a nitrodilator and a nitrogen oxide compound

Provided here are compositions and methods for treatment of vascular conditions or respiratory conditions by administering a therapeutically effective amount of a nitrogen oxide compound and a nitrodilator. The nitrogen oxide compound can be nitrite, one or more of a number of nitro-group containing compounds, a nitrate-group containing compound, an NO donor, or an endogenous NO producing amino acid. The nitrodilator can be one or more of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, amyl nitrite, nitrosothiols, or dinitrosyl iron complexes.
Owner:LOMA LINDA UNIVERSITY

Skin compatible protective care agent for application to the skin

The invention relates to a skin-compatible, nourishing, and protective agent for application to or treatment of the skin, comprising one or more active substances, in particular, but not exclusively, plant extracts or oils. According to the invention, a first mixture component is provided, which contains at least almond oil, cetyl alcohol, CBD isolate, and vitamin E or tocopherol, and a second mixture component is provided, which comprises sea salt dissolved in purified water, as well as xanthan gum and propylene glycol, wherein the first and second mixture components are combined and emulsified.
Owner:TULICHEM GMBH +1

Cannabinoid receptor 2 modulators

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
Owner:F HOFFMANN LA ROCHE & CO AG

Method for treating patient with brca-mutated cancer

A method for treating BRCA gene-mutated cancer. In the method, a drug containing hypoxia-activated prodrug compounds of formulas (1), (2) and (3) or AKR1C3 enzyme-activated prodrug compounds of formulas (4), (5), (6), (7), (8), (9), (10), (11) and (12) and salts, esters, solvates and isotopic isomers thereof, is used alone or in combination with other drugs to treat patients with BRCA gene-mutated cancer and tumors.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Association of AKR1C3 enzyme expression level through KRAS mutation and medical application

The invention relates to an AKR1C3 enzyme expression level and medical application through KRAS mutation. According to the AKR1C3 enzyme activated anticancer prodrug, KRAS gene mutation can be directly used as a detection target before medication, namely, a KRAS mutation patient is a patient with high expression of the AKR1C3 enzyme and does not need to be subjected to AKR1C3 enzyme expression level or AKR1C3RNA detection, that is to say, KRAS mutation detection positive can be used as a screening index to screen the patient with high expression of the AKR1C3 enzyme.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Nitric oxide releasing articles with enhanced albumin affinity and methods for making and using the same

PCT designated stageWO2025245356A1Peptide/protein ingredientsNitro compound active ingredientsThrombusNitric Oxide-Releasing Compound
Described herein are articles comprising a nitric oxide releasing compound and dextran bonded to at least one surface of the article, wherein a sulfonated triazine is covalently bonded to dextran. In one aspect, the articles bind to albumin, which can reduce clotting at the surface of the article and the risk of thrombosis.
Owner:UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC

Compositions and methods of treating diseases using combinations of nitrovasodilators and nitric oxide compounds - Patents.com

Provided herein are compositions and methods for treating vascular or respiratory conditions by administering a therapeutically effective amount of a nitric oxide compound and a nitrovasodilator. The nitric oxide compound can be a nitrite, one or more of several nitro-group-containing compounds, a nitrate-group-containing compound, an NO donor, or an endogenous NO-generating amino acid. The nitrovasodilator can be one or more of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, amyl nitrite, nitrosothiol, or dinitrosyl iron complex.
Owner:LOMA LINDA UNIVERSITY

Boronic acid derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).
Owner:QPEX BIOPHARMA INC

Anti-non-tuberculous mycobacteria inhibitors

The present invention provides anti-NTM compounds that target the NTM F1FO-ATP synthase. The present invention provides the use of the anti-NTM compounds as a medicament to treat NTM. The present invention also provides the use of the anti-NTM compounds as a medicament to treat NTM with a second antibiotic.
Owner:NANYANG TECH UNIV

Novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds and inhibitory activity of these compounds on carbonic anhydrase i and ii enzymes

Within the scope of the invention, 18 novel 3,5-disubstituted-1,2,4-oxadiazole derivative compounds were synthesized. The synthesized compounds were found to have high inhibitory activity on carbonic anhydrase enzymes I and II (CA I and CA II).
Owner:ANADOLU UNIVSI +1

Method and composition for restoring homeostasis, treating, and preventing degenerative diseases, achieving Anti-aging effect

Disclosed are methods to restore homeostasis in a subject in need thereof; methods of treating or preventing a degenerative disease in a subject in need thereof; and methods of achieving anti-aging effect in a subject in need thereof. The disclosed methods establishes or rebuilds a homeostatic balance between electric and magnetic components of differential and integral characteristics of electromagnetic field in cells of said subject. The methods comprise administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising various essential chemical elements and additive chemical elements specific to each essential element.
Owner:VECTOR VITALE IP LLC

Entacapone-related compounds for the treatment of injuries

The present invention provides the use of entacapone, an entacapone derivative, or a stereoisomer, hydrate, or pharmaceutically acceptable salt thereof, in a human in need thereof for treating an injury or promoting wound healing or tissue regeneration.
Owner:NAT INST OF BIOLOGICAL SCI BEIJING

Methods for treating autism spectrum disorder

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).
Owner:THE GENERAL HOSPITAL CORP

A composition for treating brain atrophy

The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and / or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and / or slowing down brain atrophy in a human subject in need thereof.
Owner:NV NUTRICIA